Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 



